1-(4-(2-(4-(2,2-dimethylbutyl)-1H-imidazol-2-yl)ethyl)phenyl)-1H-1,2,4-triazole

ID: ALA1089522

PubChem CID: 46884662

Max Phase: Preclinical

Molecular Formula: C19H25N5

Molecular Weight: 323.44

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCC(C)(C)Cc1c[nH]c(CCc2ccc(-n3cncn3)cc2)n1

Standard InChI:  InChI=1S/C19H25N5/c1-4-19(2,3)11-16-12-21-18(23-16)10-7-15-5-8-17(9-6-15)24-14-20-13-22-24/h5-6,8-9,12-14H,4,7,10-11H2,1-3H3,(H,21,23)

Standard InChI Key:  FUZUDDMIKYZEQI-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   -2.6598   -0.6208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6609   -1.4482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9461   -1.8610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2297   -1.4477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2325   -0.6172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9479   -0.2080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3738   -1.8604    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5196   -0.2020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1964   -0.6118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9093   -0.1966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6617   -0.5323    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2115    0.0832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7962    0.7959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9899    0.6212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0364    0.0876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4451    0.8043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2701    0.8087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6788    1.5253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6167    0.8083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6542    1.6083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1260   -1.5285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6766   -2.1409    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2643   -2.8538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4590   -2.6819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  6  1  1  0
  1  2  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 10  1  0
  2  7  1  0
 12 15  1  0
  3  4  2  0
 15 16  1  0
  5  8  1  0
 16 17  1  0
 17 18  1  0
  8  9  1  0
 16 19  1  0
  4  5  1  0
 16 20  1  0
  7 21  1  0
  9 10  1  0
 10 11  2  0
  2  3  1  0
  5  6  2  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24  7  1  0
M  END

Associated Targets(Human)

BRS3 Tchem Bombesin receptor subtype-3 (700 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Brs3 Bombesin receptor subtype-3 (412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Brain (4256 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 323.44Molecular Weight (Monoisotopic): 323.2110AlogP: 3.75#Rotatable Bonds: 7
Polar Surface Area: 59.39Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.14CX LogP: 3.96CX LogD: 3.78
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.72Np Likeness Score: -1.45

References

1. Liu J, He S, Jian T, Dobbelaar PH, Sebhat IK, Lin LS, Goodman A, Guo C, Guzzo PR, Hadden M, Henderson AJ, Pattamana K, Ruenz M, Sargent BJ, Swenson B, Yet L, Tamvakopoulos C, Peng Q, Pan J, Kan Y, Palyha O, Kelly TM, Guan XM, Howard AD, Marsh DJ, Metzger JM, Reitman ML, Wyvratt MJ, Nargund RP..  (2010)  Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.,  20  (7): [PMID:20219372] [10.1016/j.bmcl.2010.02.076]

Source